Wockhardt News and Updates

Keep track of all breaking news on Wockhardt from all sources in a single place.

10 Aug 2026

1826.00

-1.82%

With a pipeline of antibiotics, Wockhart looks to build a conversation on rational use and resistance

Business Line

Wockhardt Antibiotic Academy to be an open scientific learning platform to facilitate continuous medical education among healthcare professionals, says Founder Chairman Habil Khorakiwala

Number of FII/FPI investors increased from 180 to 198 in Jun 2026 qtr.

Wockhardt Ltd.

10 Aug 2026

1826.00

-1.82%

Wockhardt Q1 results: Revenue rises 26% to 929 cr, profit at 107 cr

Business Standard

Pharmaceuticals firm Wockhardt Ltd on Monday reported a consolidated profit after tax of Rs 107 crore for the first quarter ended June 30, mainly due to strong revenue growth. The company had posted a consolidated net loss of Rs 108 crore in the corresponding period of the last fiscal, Wockhardt Ltd said in a regulatory filing. Its consolidated revenue from operations in the first quarter stood at Rs 929 crore against Rs 738 crore a year ago, it added. Total expenses in the quarter under review were higher at Rs 844 crore compared to Rs 770 crore in the year-ago period, it said.

Wockhardt Ltd. is trading above its 200 day SMA of 1542.0

Wockhardt Ltd.

10 Aug 2026

1826.00

-1.82%

to see Rapid results content

Wockhardt Ltd.

06 Jul 2026

1826.00

-1.82%

Looking beyond generics: Wockhardt is showing the way in antibiotics

Business Standard

Wockhardt's FDA-approved Zaynich marks a breakthrough in India's pharmaceutical innovation, offering a new weapon against antimicrobial resistance

Wockhardt Ltd. is trading below its 30 day SMA of 1903.4

Wockhardt Ltd.

12 Jun 2026

1826.00

-1.82%

Turnaround? Or execution still under scrutiny

Not Rated: Wockhardt Ltd.

Deven Choksey

Wockhardt has transformed into an innovation-led pharmaceutical company with a strong pipeline of novel antibiotics, highlighted by the USFDA approval of Zaynich.

Wockhardt Ltd. is trading above its 200 day SMA of 1542.0

Wockhardt Ltd.

10 Jun 2026

1826.00

-1.82%

Wockhardt targets 50% of revenue from novel drugs within five years

Business Standard

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of RD

Number of FII/FPI investors increased from 180 to 198 in Jun 2026 qtr.

Beyond Zaynich: Wockhardt bets on WCK 6777 as next blockbuster jab

Business Standard | 10 Jun 2026

Wockhardt Ltd.

02 Jun 2026

1826.00

-1.82%

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What's behind the selloff?

Economic Times

Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its March quarter results. Revenue and profit saw significant year-on-year growth. Biotech operations were a key driver of this improved performance.